An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy

Author:

Lach-Trifilieff Estelle1,Minetti Giulia C.1,Sheppard KellyAnn2,Ibebunjo Chikwendu3,Feige Jerome N.1,Hartmann Steffen4,Brachat Sophie1,Rivet Helene1,Koelbing Claudia1,Morvan Frederic1,Hatakeyama Shinji1,Glass David J.3

Affiliation:

1. MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland

2. Development and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA

3. MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA

4. Integrated Biologics Profiling, Novartis Pharma, Basel, Switzerland

Abstract

ABSTRACT The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.

Publisher

American Society for Microbiology

Subject

Cell Biology,Molecular Biology

Cited by 248 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Effect of Bimagrumab on body composition: a systematic review and meta-analysis;Aging Clinical and Experimental Research;2024-09-09

2. KLF10: a point of convergence in cancer cachexia;Current Opinion in Supportive & Palliative Care;2024-07-15

3. Diagnosis and management of sarcopenia;Journal of the Korean Medical Association;2024-07-10

4. David J. Glass elected to the U.S. National Academy of Sciences;Skeletal Muscle;2024-07-09

5. Skeletal muscle dysfunction with advancing age;Clinical Science;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3